Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

for six months, a timeframe for demonstrating clinical improvement that is unique in randomized controlled studies of urate-lowering therapies.  
  • Total accounts ordering KRYSTEXXA increased to 329, a gain of 189 for the quarter.

  • A comprehensive market research study of the U.S. refractory chronic gout market was completed that demonstrated a significant market for KRYSTEXXA.

  • Four abstracts were accepted for presentation at the American College of Rheumatology Congress.

  • The executive management team expanded with the addition of a very experienced Chief Medical Officer and Chief Financial Officer.

  • Financial Results of Operations for the Three Months Ended September 30, 2011Total revenues increased to $2.6 million, or 161%, for the three months ended September 30, 2011, as compared to $1.0 million for the three months ended September 30, 2010.  The higher net sales for the three months ended September 30, 2011 were the result of the Company's launch of KRYSTEXXA, which generated approximately $1.9 million in revenue for the quarter.Cost of sales increased by $4.2 million to $4.6 million for the three months ended September 30, 2011, from $0.4 million for the three months ended September 30, 2010.  The increase for the three months ended September 30, 2011 was substantially due to a $3.4 million charge against income to reserve for excess KRYSTEXXA inventory that had expiration dates such that it was unlikely the product would be sold.

    Research and development expenses decreased by $3.1 million, or 35%, to $5.9 million for the three months ended September 30, 2011, from $9.0 million for the three months ended September 30, 2010.  The decrease for the three months ended September 30, 2011 was primarily due to costs incurred in the prior year related to commercial batches of KRYSTEXXA that were expensed as research and development expense prior to the U.S. FDA approval.  
    '/>"/>

    SOURCE Savient Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
    2. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
    3. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
    4. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
    5. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
    6. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
    7. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
    8. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
    9. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
    10. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
    11. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... YORK , 21. Mai 2015 ... DPRX ), ein Unternehmen für ... auf die Entwicklung und Vermarktung von ... konzentriert, kündigte heute eine wissenschaftliche Posterpräsentation ... Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 und ...
    (Date:5/21/2015)... -- Heidrick & Struggles (Nasdaq: HSII ), the premier ... and culture shaping worldwide, strengthens its ... the addition of Tim Dietlin to the ... Dietlin has extensive life sciences and professional services ... and Commercial functions to increase productivity, drive transformational change, ...
    (Date:5/21/2015)... , May 21, 2015  Today, ... physicians who prescribe biologics – Alliance for ... American College of Rheumatology, Biologics Prescribers Collaborative, ... Organizations, Endocrine Society, and North American Society ... sent a letter to U.S. Food and ...
    Breaking Medicine Technology:Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7Heidrick Increases Healthcare and Life Sciences Expertise 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 3Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 4
    ... 23, 2007 /PRNewswire-FirstCall/ -- Shire plc,announced that ... non-oral medication approved for treatment of,Attention Deficit ... 12 years, provided significant improvement in symptom ... 12-month open-label,study presented at the American Psychiatric ...
    ... Underscores Impact of Disease on Work Status and,Productivity, ... at Digestive Disease Week(R) 2007 (DDW), from,long-term extensions ... 2) show that subjects with moderately to severely ... in the blinded phase of the trials maintained,improvement ...
    Cached Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9
    (Date:5/24/2015)... Metamora, Michigan (PRWEB) May 24, 2015 ... allow them to take pressure measurements in patients’ bladder ... The doctor usually orders it if they have reported ... (OAB). , Women’s Excellence in Bladder Control ... with unwanted urinary leakage or problems with overall control ...
    (Date:5/24/2015)... ProPin is a set of self-animating 3D pin markers ... to pin point locations on a map, to indicate prices or ... users to choose from 30 simplistic presets with geometric design elements ... editors can easily manipulate ProPin presets as a whole. Pixel ... , Using ProPin is easy, simply drag a preset into the ...
    (Date:5/24/2015)... CA (PRWEB) May 24, 2015 ... clear indicator that the single best option for avoiding ... reveals that fitness level was the single most powerful ... for variables such as diabetes and family history of ... of maintaining lifelong heart and lung fitness. , The ...
    (Date:5/23/2015)... Diego, CA (PRWEB) May 23, 2015 ... especially small businesses, are finding it increasingly difficult to ... businesses which fail to provide adequate insurance for employees ... for businesses been such an integral part of a ... more affordable healthcare for businesses, Online USA Doctors has ...
    (Date:5/23/2015)... 23, 2015 A live auction will be ... hospitals, surgery centers and other medical facilities around the United ... endoscopy, lab, radiology, surgery, anesthesia, exam and much more. ... and Thursday, May 28 starting at 9:00am CDT each day. ... N. 25th Avenue, Melrose Park, IL 60160. Anyone can ...
    Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2
    ... of millions of dollars annually in medical care, suggesting ... improve outcomes but also save substantial amounts of money, ... nearly 150,000 people in six states. , "Substance abuse ... think," said Robin E. Clark, PhD, associate professor of ...
    ... to malignancy, study suggests , , MONDAY, Jan. 5 (HealthDay ... hormone replacement therapy may face an increased risk of ... suggests. , Interestingly, obese women who have used hormone ... face increased risk for this type of malignancy. , ...
    ... National Hot Tea Month, the Height of the Cold and Flu ... and is also the height of the dreaded "cold and flu ... Americans affected by the cold and flu this year, which leads ... one do to avoid the cold and flu?The CDC strongly recommends ...
    ... During the Same Study Period, According To New ... Arlington Medical Resources (AMR), a provider of ... imaging industries, finds that the number of micro-bubble ... increased by more than 50 percent, to nearly ...
    ... Jan. 5 Vocollect Healthcare Systems, Inc.,announces ... Louisiana, is,deploying AccuNurse(R) voice-assisted care in four ... part of its implementation, Central Control will,begin ... in the next two,largest facilities -- Camelot ...
    ... of a Survey Kiosk buyer,s guide. The guide explains how ... their customers by capturing real-time in-store customer feedback. , ... ... 2009 -- Opinionmeter International, developer of the award winning customer ...
    Cached Medicine News:Health News:Substance abuse adds millions to Medicaid's total health care costs 2Health News:Substance abuse adds millions to Medicaid's total health care costs 3Health News:Obesity Linked to Ovarian Cancer 2Health News:Obesity Linked to Ovarian Cancer 3Health News:Flu Season is Tea Time 2Health News:Micro-Bubble Echo Contrast Procedures Continue to Rebound in October 2008 2Health News:Micro-Bubble Echo Contrast Procedures Continue to Rebound in October 2008 3Health News:Central Control is First Louisiana-Based Organization to Deploy Voice-Assisted Care 2Health News:Central Control is First Louisiana-Based Organization to Deploy Voice-Assisted Care 3Health News:Guide for Using Survey Kiosks for Instant Customer Feedback Sponsored by Opinionmeter 2Health News:Guide for Using Survey Kiosks for Instant Customer Feedback Sponsored by Opinionmeter 3
    ... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
    ... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
    ... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
    ... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
    Medicine Products: